Compare ALNT & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALNT | HROW |
|---|---|---|
| Founded | 1962 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 1995 | 2008 |
| Metric | ALNT | HROW |
|---|---|---|
| Price | $117.41 | $30.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $118.00 | $65.00 |
| AVG Volume (30 Days) | 186.4K | ★ 537.0K |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 0.13% | N/A |
| EPS Growth | 67.09 | ★ 71.43 |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $554,478,000.00 | N/A |
| Revenue This Year | $8.52 | $28.81 |
| Revenue Next Year | $9.07 | $53.97 |
| P/E Ratio | $127.66 | ★ N/A |
| Revenue Growth | ★ 4.62 | N/A |
| 52 Week Low | $42.42 | $28.54 |
| 52 Week High | $120.56 | $54.98 |
| Indicator | ALNT | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 66.21 | 25.71 |
| Support Level | $81.89 | $28.54 |
| Resistance Level | $118.67 | $35.43 |
| Average True Range (ATR) | 5.00 | 1.24 |
| MACD | 1.28 | -0.18 |
| Stochastic Oscillator | 90.59 | 9.45 |
Allient Inc, formerly Allied Motion Technologies Inc designs, manufactures, and sells precision and specialty controlled motion components and systems. The firm mainly caters to the Industrial, Vehicle, Aerospace & Defense, and Medical sectors. It mainly operates and sells across the United States, Canada, South America, Europe, and Asia. Its products and solutions include nano precision positioning systems, servo control systems, motion controllers, digital servo amplifiers and drives, brushless servo, torque, and coreless motors, brush motors, integrated motor drives, gear motors, gearing, incremental and absolute optical encoders, active (electronic) and passive (magnetic) filters for power quality and harmonic issues.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.